Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Corbus Pharmaceuticals Holdings (CRBP) Long-Term Debt Repayments (2016 - 2020)

Corbus Pharmaceuticals Holdings has reported Long-Term Debt Repayments over the past 6 years, most recently at $108936.0 for Q3 2020.

For Q3 2020, Long-Term Debt Repayments rose 9.67% year-over-year to $108936.0; the TTM value through Sep 2020 reached $358729.0, up 446.01%, while the annual FY2022 figure was $1.5 million, N/A changed from the prior year.
Long-Term Debt Repayments for Q3 2020 was $108936.0 at Corbus Pharmaceuticals Holdings, down from $323969.0 in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $351326.0 in Q4 2017 and troughed at -$393930.0 in Q4 2019.
A 5-year average of $69535.6 and a median of $116358.0 in 2017 define the central range for Long-Term Debt Repayments.
Biggest five-year swings in Long-Term Debt Repayments: soared 10269.17% in 2017 and later tumbled 204.68% in 2018.
Year by year, Long-Term Debt Repayments stood at $1119.0 in 2016, then skyrocketed by 31296.43% to $351326.0 in 2017, then plummeted by 193.53% to -$328605.0 in 2018, then dropped by 19.88% to -$393930.0 in 2019, then surged by 127.65% to $108936.0 in 2020.
Business Quant data shows Long-Term Debt Repayments for CRBP at $108936.0 in Q3 2020, $323969.0 in Q2 2020, and $319754.0 in Q1 2020.